Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system. For more information, please visit www.shinobitx.com.
Total raised: $51M
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.12.2023 | Series A | $51M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 26.12.2023 | Shinobi announced their $51M Series A funding | Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS-T cell ... | eightroads... |
| 12.12.2023 | Shinobi Therapeutics, Inc. Shinobi Therapeutics completes $5... | Shinobi Therapeutics Co., Ltd. Shinobi Therapeutics completes $51 million Series A to develop low-im... | re-how.net... |
| 12.12.2023 | Shinobi Therapeutics Raises $51M in Series A Funding | Shinobi Therapeutics, a San Francisco, CA- and Kyoto, Japan-based biotechnology company developing a... | finsmes.co... |
| 12.12.2023 | Exclusive: Shinobi raises $51M to take on cell therapy chall... | - | fprimecapi... |